Matica Biotechnology, a US subsidiary of CHA Biotech, has appointed Laura Parks as EVP of commercial operations and Heather Sugrue as VP of alliance management to enhance its cell and gene therapy contract manufacturing capabilities.
SK pharmteco completed its second facility for Cell and Gene Therapies (C>) manufacturing in Europe, doubling its viral vector production capacity to 10,000 square meters (2.47 acres).
Matica Biotechnology, a U.S. subsidiary of CHA Biotech, is aiming to capitalize on the growing market of cell and gene therapies by offering a contract manufacturing and development service for the drug makers.
Korean pharmaceutical companies are making big bets on the cell and gene therapy market, the sector that many consider to be the next game-changer in the global pharma world.
Matica Biotechnology, a wholly-owned subsidiary of CHA Biotech, celebrated the completion of a cell and gene therapy manufacturing facility in College Station, Texas, Tuesday.
Korea JoongAng Daily Sitemap